Enanta Pharmaceuticals, Inc. announced it has filed a patent infringement lawsuit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries.
The lawsuit, action number 35071/2025, seeks a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent). This legal action targets Pfizer's COVID-19 antiviral, Paxlovid.
This filing expands Enanta's legal efforts to protect its intellectual property related to COVID-19 antivirals into 18 EU countries. The move underscores the company's commitment to asserting its patent rights on a global scale.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.